AU2003267722A1 - Imidazol-1-ylmethyl pyridazine derivatives - Google Patents

Imidazol-1-ylmethyl pyridazine derivatives

Info

Publication number
AU2003267722A1
AU2003267722A1 AU2003267722A AU2003267722A AU2003267722A1 AU 2003267722 A1 AU2003267722 A1 AU 2003267722A1 AU 2003267722 A AU2003267722 A AU 2003267722A AU 2003267722 A AU2003267722 A AU 2003267722A AU 2003267722 A1 AU2003267722 A1 AU 2003267722A1
Authority
AU
Australia
Prior art keywords
imidazol
ylmethyl
pyridazine derivatives
pyridazine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267722A
Other languages
English (en)
Other versions
AU2003267722A8 (en
Inventor
Bingson Han
George Maynard
Linghong Xie
Yuelian Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU2003267722A1 publication Critical patent/AU2003267722A1/en
Publication of AU2003267722A8 publication Critical patent/AU2003267722A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003267722A 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives Abandoned AU2003267722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/416,660 2002-10-01
US41666002P 2002-10-07 2002-10-07
PCT/IB2003/004382 WO2004031174A1 (en) 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives

Publications (2)

Publication Number Publication Date
AU2003267722A1 true AU2003267722A1 (en) 2004-04-23
AU2003267722A8 AU2003267722A8 (en) 2004-04-23

Family

ID=32069951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267722A Abandoned AU2003267722A1 (en) 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives

Country Status (7)

Country Link
US (1) US7122546B2 (https=)
EP (1) EP1549636A1 (https=)
JP (1) JP2006504714A (https=)
CN (1) CN100579579C (https=)
AU (1) AU2003267722A1 (https=)
CA (1) CA2495698A1 (https=)
WO (1) WO2004031174A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335732T1 (de) * 2002-11-08 2006-09-15 Neurogen Corp 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
EP1594848A1 (en) 2003-02-19 2005-11-16 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
WO2005012306A2 (en) * 2003-07-25 2005-02-10 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
AU2008205169B2 (en) 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014094182A1 (en) * 2012-12-21 2014-06-26 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof
HRP20210764T1 (hr) 2017-03-30 2021-07-09 Bristol-Myers Squibb Company Postupak za pripremu 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazin-3-karboksamida

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
AU2001270297A1 (en) * 2000-06-30 2002-01-14 Neurogen Corporation 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
JP2006515278A (ja) * 2002-05-08 2006-05-25 ニューロジェン コーポレイション 置換イミダゾリルメチルピリジン及びピラジン誘導体並びにそれらのｇａｂａａ受容体リガンドとしての使用
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
ATE335732T1 (de) 2002-11-08 2006-09-15 Neurogen Corp 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
CA2524376A1 (en) 2003-05-05 2004-12-16 Neurogen Corporation Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands

Also Published As

Publication number Publication date
WO2004031174A1 (en) 2004-04-15
WO2004031174A8 (en) 2005-04-21
US20040077653A1 (en) 2004-04-22
CA2495698A1 (en) 2004-04-15
US7122546B2 (en) 2006-10-17
CN100579579C (zh) 2010-01-13
AU2003267722A8 (en) 2004-04-23
JP2006504714A (ja) 2006-02-09
EP1549636A1 (en) 2005-07-06
CN1717250A (zh) 2006-01-04

Similar Documents

Publication Publication Date Title
AU2003292429A1 (en) Pyrazole compounds
AU2003296586A1 (en) Pyridazinone derivatives as cdk2-inhibitors
AU2003224640A1 (en) Integrated putter system
PL371918A1 (en) Pyridazine derivatives
AU2003239909A1 (en) Enhanced-service provision
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003260919A1 (en) Azapurine derivatives
AU2003227712A1 (en) Tetrahydroisoquinoline derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003281039A1 (en) Imidazole derivative
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003267722A1 (en) Imidazol-1-ylmethyl pyridazine derivatives
AU2003206730A1 (en) Fitting
AU2003227976A1 (en) Meeting aid
AU2003223475A1 (en) Substituted pyrazine derivatives
AU2003271584A1 (en) Opacificiers
AU2003262681A1 (en) Hemo-aide
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2002953019A0 (en) Azole derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase